trending Market Intelligence /marketintelligence/en/news-insights/trending/1eym_h-ygw_u1hsgaceema2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Report: Bayer planning job cuts, outsourcing to bolster pharma unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Bayer planning job cuts, outsourcing to bolster pharma unit

Germany's Bayer Aktiengesellschaft is considering downsizing its drug research and development activities to give itself financial room to buy the rights to promising treatments from other biotech firms, Reuters reported, citing a person familiar with the matter.

The German giant is under pressure from investors to undertake licensing deals or make purchases to ensure the continued independence of its pharmaceutical division, the report said.

The $62.5 billion acquisition of Monsanto Co. has reshaped Bayer's revenue streams, giving greater prominence to the crop sciences unit which was in the shadow of the company's pharmaceutical and consumer health businesses.

The ongoing review is evaluating outsourcing drug testing services to cheaper contractors and will be complete in November, the news agency said.